BAYN Stock Overview
Together its subsidiaries, operates as a life science company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €19.54 |
| 52 Week High | €36.09 |
| 52 Week Low | €19.40 |
| Beta | 1 |
| 11 Month Change | -25.12% |
| 3 Month Change | -29.47% |
| 1 Year Change | -40.44% |
| 33 Year Change | -58.83% |
| 5 Year Change | -71.96% |
| Change since IPO | 43.50% |
Recent News & Updates
Recent updates
Benign Growth For Bayer Aktiengesellschaft (ETR:BAYN) Underpins Stock's 25% Plummet
Nov 21
These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively
Sep 13Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now
Aug 09These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively
Jun 11The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet
May 07These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way
Jan 18Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?
Dec 27Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt
Oct 15Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Aug 05Shareholder Returns
| BAYN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.0% | -7.0% | -0.4% |
| 1Y | -40.4% | -21.6% | 7.1% |
Return vs Industry: BAYN underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: BAYN underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| BAYN volatility | |
|---|---|
| BAYN Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BAYN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BAYN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 94,245 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| BAYN fundamental statistics | |
|---|---|
| Market cap | €19.20b |
| Earnings (TTM) | -€880.00m |
| Revenue (TTM) | €46.74b |
0.4x
P/S Ratio-21.8x
P/E RatioIs BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAYN income statement (TTM) | |
|---|---|
| Revenue | €46.74b |
| Cost of Revenue | €20.03b |
| Gross Profit | €26.71b |
| Other Expenses | €27.59b |
| Earnings | -€880.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 05, 2025
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 57.15% |
| Net Profit Margin | -1.88% |
| Debt/Equity Ratio | 134.1% |
How did BAYN perform over the long term?
See historical performance and comparison